What type of treatment is Lapatinib classified as?

Lapatinib is classified as targeted therapy because it specifically inhibits certain proteins that contribute to the growth and spread of cancer cells, particularly in breast cancer. Unlike traditional chemotherapy, which can affect a wide range of rapidly dividing cells, targeted therapies are designed to interfere with specific molecular targets that are associated with cancer.

Lapatinib targets the human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR). By binding to these receptors, it blocks the signals that promote cancer cell proliferation and survival. This selectivity helps to minimize damage to normal cells and can lead to improved outcomes for patients with HER2-positive breast cancer.

In contrast, chemoimmunotherapy combines elements of chemotherapy with immunotherapy, which is not the primary function of Lapatinib. Hormonal therapy focuses on manipulating hormonal levels or actions, which does not apply to the mechanism of Lapatinib. Radiation therapy, on the other hand, uses high-energy particles or waves to destroy or damage cancer cells and is distinct in its approach compared to targeted therapy.